InsiderTrades.com logo
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.
Alexander O. Schuth net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Alexander Schuth Biography and Net Worth

COO of Denali Therapeutics
Alex Schuth is Chief Operating Officer of Denali Therapeutics. He is a co-founder of the company and responsible for portfolio management, corporate development, and the legal group.

Since 2015, Alex and his team have helped build and advance a broad portfolio of therapeutic drug candidates from discovery stage to clinical development and established over 30 collaborations with partners in academia and industry to accelerate the discovery and development of medicines for neurodegenerative diseases.

Alex previously held various operational and leadership positions during a 10-year tenure at Genentech, including Head of Neuroscience Partnering, and contributed to the growth and success of Genentech’s pipeline across several therapeutic areas. Before joining Genentech, Alex worked in Merrill Lynch’s investment banking group in London, where his responsibilities included executing equity capital market transactions.

Alex holds an M.D. degree from the Charite Medical School at the Humboldt University in Berlin, Germany, and an M.B.A. from the Wharton School of the University of Pennsylvania. Provided by Tagnifi.

What is Alexander O. Schuth's net worth?

The estimated net worth of Alexander O. Schuth is at least $7.91 million as of July 17th, 2023. Dr. Schuth owns 528,691 shares of Denali Therapeutics stock worth more than $7,909,217 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Schuth may own. Additionally, Dr. Schuth receives an annual salary of $737,200.00 as COO at Denali Therapeutics. Learn More about Alexander O. Schuth's net worth.

How old is Alexander O. Schuth?

Dr. Schuth is currently 51 years old. There are 3 older executives and no younger executives at Denali Therapeutics. The oldest executive at Denali Therapeutics is Dr. Marc Tessier-Lavigne Ph.D., Co-Founder & Independent Director, who is 64 years old. Learn More on Alexander O. Schuth's age.

What is Alexander O. Schuth's salary?

As the COO of Denali Therapeutics Inc., Dr. Schuth earns $737,200.00 per year. The highest earning executive at Denali Therapeutics is Dr. Ryan J. Watts Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Alexander O. Schuth's salary.

How do I contact Alexander O. Schuth?

The corporate mailing address for Dr. Schuth and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at [email protected]. Learn More on Alexander O. Schuth's contact information.

Has Alexander O. Schuth been buying or selling shares of Denali Therapeutics?

Alexander O. Schuth has not been actively trading shares of Denali Therapeutics during the last ninety days. Learn More on Alexander O. Schuth's trading history.

Who are Denali Therapeutics' active insiders?

Denali Therapeutics' insider roster includes Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.

Are insiders buying or selling shares of Denali Therapeutics?

In the last twelve months, insiders at the sold shares 31 times. They sold a total of 210,517 shares worth more than $4,491,915.99. The most recent insider tranaction occured on April, 15th when Director Vicki L Sato sold 1,666 shares worth more than $30,471.14. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.

Information on this page was last updated on 4/15/2024.

Alexander O. Schuth Insider Trading History at Denali Therapeutics

See Full Table

Alexander O. Schuth Buying and Selling Activity at Denali Therapeutics

This chart shows Alexander O. Schuth's buying and selling at Denali Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Denali Therapeutics Company Overview

Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $14.96
Low: $14.58
High: $15.25

50 Day Range

MA: $19.10
Low: $15.56
High: $23.35

2 Week Range

Now: $14.96
Low: $14.56
High: $33.31

Volume

1,140,416 shs

Average Volume

1,180,445 shs

Market Capitalization

$2.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.